Diagnostic Enzymes Market - Forecasts from 2024 to 2029

The diagnostic enzymes market was valued at US$4.646 billion in 2022.

The notion of employing enzymes to identify and analyze biological abnormalities is based on the fact that the activity of endogenous enzymes is sensitive to health. In addition, variations in the concentration of the substrate, which are also a sign of physiological abnormalities, can be detected by enzymes. For instance, measuring cholesterol using cholesterol oxidase might identify probable cardiovascular problems or high blood pressure. In biotechnologies, enzymes may be employed to create analysis and detection techniques like the enzyme-linked immunosorbent assay (ELISA) and coupled multi-enzyme reaction assays.

Increase in geriatric population

The diagnostic enzymes market is expected to expand more quickly as a result of the aging population. By 2030, 1 in 6 individuals will be 60 or older, with emerging countries being primarily responsible for this growth, according to the World Health Organisation. Between 2020 and 2050, the number of persons 80 or older is projected to treble, reaching 426 million. Elderly patients typically have hearing loss, cataracts and refractive errors, back and neck pain and osteoarthritis, diabetes, depression, and dementia, which contributes to the rising usage of generic medications. People are more prone to several diseases at once as they get older which can fuel the growth of the diagnostic enzymes market.

Diagnostic Enzymes for Diabetes Diagnosis

The quickest and easiest way to identify diabetes is with a blood sugar test. Enzymes involved in the metabolism of glucose are created to react with glucose and, as a result, to detect the presence of glucose in blood samples. Creative Enzymes carries a wide range of diabetes-related enzymes from various suppliers. For instance, a lack of glucose-6-phosphate dehydrogenase has been linked to an increased risk of developing diabetes. For clinical blood sugar tests, glucose oxidase and glucose dehydrogenase are most frequently utilized. To start using glucose, hexokinase catalyzes the phosphorylation of glucose to produce glucose 6-phosphate.

Diagnostic enzymes for liver function test

The therapy of individuals with hepatic dysfunction and early detection of liver illnesses depend on the results of liver function tests. To identify the presence of odd compounds linked to various forms of liver injury or disorders, a variety of enzymatic reactions are created which boosts the diagnostic enzymes industry. For instance, with their diagnostic enzyme products, Creative Enzymes has supported the clinical and scientific usage of liver function assessment. The business includes several liver function-related enzymes from various natural sources or biochemical syntheses to satisfy the unique requirements of the consumer. Malate dehydrogenase, D-lactate dehydrogenase, alcohol dehydrogenase, and alkaline phosphatase are all available in either natural or recombinant forms.

Rising demand for nuclease enzymes

An enzyme called nuclease divides the DNA and RNA nucleotide chain into smaller pieces. The DNA molecule is broken down by the nuclease enzyme, as well as the phosphodiester bonds connecting one nucleotide to another in the DNA strand. Exonucleases and endonucleases are the two distinct kinds of nucleases. Additionally, in March 2023, Nuclease 46L (N046L), a novel enzyme from enzyme experts Biocatalysts Ltd, is now available for the breakdown of various nucleic acids from a variety of sources. It was created primarily as a low-cost method to get rid of DNA in a variety of biotechnology applications. These developments are essential for the development of the diagnostic enzymes industry.

In North America, it is projected that the diagnostic enzymes market will grow steadily.

North American region is expected to take a leading position as a result of the expanding demand for enzymes and the prevalence of infectious illnesses there. For instance, the FDA has authorized COVID-19 laboratory-developed diagnostics for use in emergencies to tackle the ongoing outbreak. For the detection of SARS-CoV-2, the majority of these emergency usage authorizations also employ RT-PCR-based testing and enzyme-linked immunosorbent tests. Because RT-PCR uses a lot of enzymes, the development of such assays is projected to be profitable in the North American diagnostic enzymes market.

Government initiatives for diagnostic enzymes

• Following the National Health Mission, States and UTs get financial assistance to offer free basic medications in public health facilities following the demands stated in their Programme Implementation Plans (PIPs) and the overall resource envelope. To guarantee universal access to necessary medications, the ministry has proposed that a facility-specific Essential Drugs List (EDL) be made accessible at public healthcare institutions.
• Rapid diagnostic tests (RDTs) have a great deal of potential for quickly and accurately identifying infectious organisms and determining their susceptibility to various types of antibiotics. As a result, they are expected to play a bigger role in antimicrobial stewardship (AMS) programs in the future. RDT usage is already encouraged by international standards for the deployment of AMS in a few particular contexts.

Diagnostic enzymes Products

• EKF Diagnostics, Diagnostic enzymes are produced by EKF Life Sciences and utilised as clinical diagnostic reagents. Among these are salicylate hydroxylase, beta-hydroxybutyrate dehydrogenase, and arylacylamidase. These diagnostic enzymes are sold commercially for use in the manufacturing of third-party clinical diagnostic firms' reagents as well as OEM reagents under the Stanbio Chemistry brand.
• Asahi Kasei Pharma, Controlling blood sugar properly is crucial for avoiding diabetic complications. The glycated albumin measures the average glycemia throughout the two weeks before the blood sample. Glycated albumin is measured using the LucicaTM GA-L liquid reagent test kit, which was introduced in 2004. Glycated albumin was included as a laboratory test component for donated blood by the Japan Red Cross in 2009.

Market Key Developments

• In June 2023, scientists from the Indian Institute of Science created a fluorogenic probe to identify an enzyme associated with the early stages of the neurodegenerative illness Alzheimer's.
• In February 2023, a pioneer in the production and delivery of diagnostic enzymes, Creative Enzymes, and research diagnostics. The company recently included pancreatic and kidney enzymes.
• In December 2022, Ginkgo Enzyme Services was launched, according to Ginkgo Bioworks, which is developing the top platform for cell programming and biosecurity. Ginkgo Enzyme Services is supported by optimized, patented bacterial and fungal host strains, machine learning-guided protein design, and ultra-high throughput screening.

Segmentation:

By Type

• Taq Polymerase
• MMLV RT
• HIV RT
• UNG
• RNase Inhibitors
• Others

By Product Type

• Molecular Enzymes
• Clinical Enzymes

By Application

• Diabetes
• Oncology
• Cardiology
• Infectious Diseases
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others